Abstract
The development of dual-targeting drug delivery system is helpful to overcome the poor physiochemical properties of chemotherapeutic agents. The RGD sequence has a potential dual-targeting property, with which the chemotherapeutic agents can be delivered to bone tissue and tumor. And the Janus dendrimer which consists of two dendrons with different tasks is useful for improving the effect of polymer on pharmacokinetic properties. In this paper, a Janustype peptide dendrimer which consisted of RGD dimer and 5-FU dimer was synthesized and well characterized by 1H NMR and MS techniques, as well as the other three compounds for contrast. The hydroxyapatite binding assay and drug release study were evaluated. The Janus-type dendrimer with both enhanced targeting property and optimized release property, may reduce the side effects in normal tissues and have potential sustained-release effect. Thus, it may represent a novel opportunity to apply the versatile Janus-type dual-targeting delivery system to applications in bone tumor treatment.
Keywords: Bone cancer, dual-targeting, hydroxyapatite, in vitro, Janus dendrimer, peptide, RGD.
Letters in Organic Chemistry
Title:Dual-targeting Janus Dendrimer Based Peptides for Bone Cancer: Synthesis and Preliminary Biological Evaluation
Volume: 10 Issue: 8
Author(s): Bo Jiang, Jing Zhao, Yanhua Li, Dongsheng He, Junzhu Pan, Junhan Cao and Li Guo
Affiliation:
Keywords: Bone cancer, dual-targeting, hydroxyapatite, in vitro, Janus dendrimer, peptide, RGD.
Abstract: The development of dual-targeting drug delivery system is helpful to overcome the poor physiochemical properties of chemotherapeutic agents. The RGD sequence has a potential dual-targeting property, with which the chemotherapeutic agents can be delivered to bone tissue and tumor. And the Janus dendrimer which consists of two dendrons with different tasks is useful for improving the effect of polymer on pharmacokinetic properties. In this paper, a Janustype peptide dendrimer which consisted of RGD dimer and 5-FU dimer was synthesized and well characterized by 1H NMR and MS techniques, as well as the other three compounds for contrast. The hydroxyapatite binding assay and drug release study were evaluated. The Janus-type dendrimer with both enhanced targeting property and optimized release property, may reduce the side effects in normal tissues and have potential sustained-release effect. Thus, it may represent a novel opportunity to apply the versatile Janus-type dual-targeting delivery system to applications in bone tumor treatment.
Export Options
About this article
Cite this article as:
Jiang Bo, Zhao Jing, Li Yanhua, He Dongsheng, Pan Junzhu, Cao Junhan and Guo Li, Dual-targeting Janus Dendrimer Based Peptides for Bone Cancer: Synthesis and Preliminary Biological Evaluation, Letters in Organic Chemistry 2013; 10 (8) . https://dx.doi.org/10.2174/15701786113109990024
DOI https://dx.doi.org/10.2174/15701786113109990024 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs
Current Pharmaceutical Biotechnology Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry Drug Evolution Concept in Drug Design: 2. Chimera Method
Medicinal Chemistry Green Synthesis and Antioxidant Activity of Novel γ-Cyano-α- hydroxyphosphonate Derivatives
Medicinal Chemistry Recent Developments of Small Molecule EGFR Inhibitors Based on the Quinazoline Core Scaffolds
Anti-Cancer Agents in Medicinal Chemistry s-Proline Covalented Silicapropyl Modified Magnetic Nanoparticles: Synthesis, Characterization, Biological and Catalytic Activity for the Synthesis of thiazolidin-4- ones
Current Organic Synthesis Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP
Current Pharmaceutical Analysis Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Quantitative Structure-activity Relationships of Imidazole-containing Farnesyltransferase Inhibitors Using Different Chemometric Methods
Medicinal Chemistry Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer
Current Proteomics Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes
Current Drug Metabolism Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer
Current Drug Targets